Prevalence of non 16/18 high risk human papilloma virus as a quality metric in gynecological cytology.
cervical cytology
high risk HPV subtypes
human papilloma virus
quality improvement
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
revised:
29
03
2024
received:
27
12
2023
accepted:
12
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Human papillomavirus (HPV) is the most common sexually transmitted pathogen that causes anogenital disease. Cervical screening by cytology and HPV testing (co-testing) are important in prevention of cervical cancer. The Bethesda System category of atypical squamous cells (ASC) is used when a neoplastic process cannot be confidently identified. In such cases, the differential diagnosis is broad and includes benign conditions. Monitoring of ASC/SIL ratio is a commonly used laboratory quality assurance measure to prevent over- or under-use of this category. High risk human papillomavirus (hr-HPV) has been used in conjunction with the ASC/SIL ratio in determining whether a particular pathologist is over/under-using the indefinite category. However, the laboratory overall sample population prevalence rate of hr-HPV subtypes has not been previously examined for association with the ASC rate. In this study, the relationships between ASC/SIL ratio and hr-HPV prevalence rate and hr-HPV subtypes (16/18 and non-16/18) to the laboratory ASC prevalence were studied. The results demonstrate that HPV non-16/18 is the main subtype which is associated with ASC-US category. A large proportion of non-16/18 HPV-related cases are seen in young patients, which largely abates by the by fourth decade. In addition, there are differences in the ASC/SIL ratio for HPV 16/18 and non-16/18 types. The overall ASC/SIL ratio is an average of the ASC/SIL rate for the non-16/18 population and the HPV 16/18 population. Instead of basing the laboratory and practitioners' quality indicator solely on ASC/SIL ratio, the overall prevalence of HPV and its subtype ratio should also be reported as they are more reflective of laboratory performance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncol. 2010;11(11):1048‐1056.
Nascimento AF, Cibas ES. The ASC/SIL ratio for cytopathologists as a quality control measure: a follow‐up study. Am J Clin Pathol. 2007;128(4):653‐656.
Goyal A, Street J, Alperstein SA, Siddiqui MT. HPV test result monitoring of different Bethesda categories in gynaecologic cytology: a valuable quality assurance measure. Diagn Cytopathol. 2018;46(11):914‐918.
Cibas ES, Zou KH, Crum CP, Kuo F. Using the rate of positive high‐risk HPV test results for ASC‐US together with the ASC‐US/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol. 2008;129(1):97‐101.
Moriarty AT, Schwartz MR, Eversole G, et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. Arch Pathol Lab Med. 2008;132(8):1290‐1294. doi:10.5858/2008‐132‐1290‐hptarr
Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in prevalence of human papillomavirus vaccine‐type infection among females after introduction of vaccine—United States, 2003–2018. MMWR Morb Mortal Wkly Rep. 2021;70(12):415‐420.
Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine‐type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis. 2016;63(10):1281‐1287.
Moriarty AT, Nayar R, Arnold T, et al. The Tahoe study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med. 2014;138(9):1182‐1185. doi:10.5858/arpa.2012‐0115‐CP
Abstracts and case studies from the College of American Pathologists 2023 annual meeting (CAP23). Arch Pathol Lab Med. 2023;147(9):e2‐e154. doi:10.5858/arpa.2023‐0258‐AB